Dixon Hubard Feinour & Brown’s Alaunos Therapeutics TCRT Stock Holding History

Dixon Hubard Feinour & Brown’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-131	Closed	-$50K	–	200
2020 Q4	$50K	Hold	131	–	–	0.01%	179
2020 Q3	$50K	Hold	131	–	–	0.01%	179
2020 Q2	$59K	Hold	131	–	–	0.02%	183
2020 Q1	$48K	Hold	131	–	–	0.02%	165
2019 Q4	$93K	Hold	131	–	–	0.02%	179
2019 Q3	$84K	Hold	131	–	–	0.02%	176
2019 Q2	$115K	Hold	131	–	–	0.03%	177
2019 Q1	$76K	Hold	131	–	–	0.02%	171
2018 Q4	$37K	Hold	131	–	–	0.01%	162
2018 Q3	$63K	Hold	131	–	–	0.02%	177
2018 Q2	$59K	Hold	131	–	–	0.02%	165
2018 Q1	$77K	Hold	131	–	–	0.02%	188
2017 Q4	$81K	Sell	131 -52	-28%	-$37.4K	0.02%	188
2017 Q3	$168K	Hold	183	–	–	0.05%	177
2017 Q2	$170K	Hold	183	–	–	0.05%	176
2017 Q1	$174K	Hold	183	–	–	0.05%	175
2016 Q4	$147K	Hold	183	–	–	0.05%	167
2016 Q3	$154K	Sell	183 -33	-15%	-$26.5K	0.05%	168
2016 Q2	$178K	Hold	216	–	–	0.06%	164
2016 Q1	$255K	Hold	216	–	–	0.08%	144
2015 Q4	$269K	Buy	216 +1	+0.5%	+$1.65K	0.09%	140
2015 Q3	$291K	Buy	215 +106	+97%	+$175K	0.11%	127
2015 Q2	$197K	Buy	+109	New	+$169K	0.06%	178

Other funds holding TCRT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Dixon Hubard Feinour & Brown's TCRT Position: Q1 2021 in Review

Dixon Hubard Feinour & Brown sold out of Alaunos Therapeutics (TCRT) in Q1 2021, closing a stake of 131 shares — an estimated $50K sold.

Dixon Hubard Feinour & Brown first reported a position in TCRT in Q2 2015 and held it in 23 quarters. The position peaked at $291K in Q3 2015. 150 funds tracked by Wall St. Rank hold TCRT as of Q1 2021.

Dixon Hubard Feinour & Brown reported no remaining Alaunos Therapeutics position as of Q1 2021 after selling out during the quarter.
Dixon Hubard Feinour & Brown sold 131 Alaunos Therapeutics shares in Q1 2021, an estimated $50K.
Dixon Hubard Feinour & Brown first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 23 quarters.
Dixon Hubard Feinour & Brown's Alaunos Therapeutics position peaked at $291K in Q3 2015.
150 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2021.

Based on Dixon Hubard Feinour & Brown's 13F filing for Q1 2021, filed 11 May 2021.